IMO, the data from that study lack internal consistency. The reason given is that some participants dropped out and therefore could not be counted as "cures". Fine. But the Daptomycin data do show a progression of effectiveness that is consistent.
It is possible/likely? that the previous study had some "issues", and the new study does not. So leave the old one labled Polymedix and put the new one under the Cellceutix banner.